|
62 Companies |
|
89 Products |
|
89 Products |
|
76 Mechanisms of Action |
|
2 Trials |
|
652 News |
|
| «12345678910111213...1314» |
- thyroxine / Generic mfg.
Trial primary completion date: Selenium Supplementation in Pregnancy (clinicaltrials.gov) - Oct 28, 2014
P4, N=150, Recruiting, Sponsor: University of Roma La Sapienza
Trial primary completion date: May 2014 --> May 2015
- || Mekinist (trametinib) / Novartis, BeiGene, pazopanib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Oct 23, 2014
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Oct 2014 --> May 2015
- Iclusig (ponatinib) / Takeda
Enrollment change, Trial primary completion date: Ponatinib for Advanced Medullary Thyroid Cancer (clinicaltrials.gov) - Oct 23, 2014
P2, N=31, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2014 --> May 2015 N=48 --> 31 | Trial primary completion date: Mar 2016 --> Sep 2016
- Trial primary completion date: Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=500, Recruiting, Sponsor: University Hospital, Rouen
N=48 --> 31 | Trial primary completion date: Mar 2016 --> Sep 2016 Trial primary completion date: Dec 2014 --> Jun 2016
- Trial primary completion date, Cytology: SWEETMAC: Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=120, Recruiting, Sponsor: Centre Francois Baclesse
Trial primary completion date: Dec 2014 --> Jun 2016 Trial primary completion date: Nov 2014 --> Nov 2015
- Enrollment closed: Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=46, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: Nov 2014 --> Nov 2015 Recruiting --> Active, not recruiting
- Trial primary completion date, Surgery: Acupuncture for Reduction of Inflammation (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=30, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Apr 2015
- ||| Enrollment open: MyEndo-Thyroid: Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=2500, Enrolling by invitation, Sponsor: International Islamic University Malaysia
Trial primary completion date: Dec 2014 --> Apr 2015 Not yet recruiting --> Enrolling by invitation
- Enrollment open, Trial primary completion date: The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=120, Recruiting, Sponsor: Cyprus University of Technology
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial primary completion date: May 2014 --> May 2015
- |||| thyroxine / Generic mfg.
Trial completion, Trial primary completion date: Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation (clinicaltrials.gov) - Oct 10, 2014
P2, N=90, Completed, Sponsor: Takeda
Not yet recruiting --> Recruiting | Trial primary completion date: May 2014 --> May 2015 Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014
- Trial primary completion date: To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer (clinicaltrials.gov) - Oct 2, 2014
P1, N=30, Active, not recruiting, Sponsor: AHS Cancer Control Alberta
Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Jun 2014 Trial primary completion date: Mar 2013 --> Sep 2015
- | Caprelsa (vandetanib) / Sanofi
Trial completion, Monotherapy, Metastases: A Study To Assess ZD6474 (ZACTIMA (clinicaltrials.gov) - Oct 2, 2014
P2, N=22, Completed, Sponsor: AstraZeneca
Trial primary completion date: Mar 2013 --> Sep 2015 Active, not recruiting --> Completed
- sorafenib / Generic mfg.
Trial primary completion date, Metastases: Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients (clinicaltrials.gov) - Sep 30, 2014
P2, N=16, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Feb 2015
- | Caprelsa (vandetanib) / Sanofi
Trial completion, Metastases: Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma (clinicaltrials.gov) - Sep 29, 2014
P1/2, N=16, Completed, Sponsor: AstraZeneca
Trial primary completion date: Aug 2015 --> Feb 2015 Active, not recruiting --> Completed
- Enrollment open, Surgery: Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=138, Recruiting, Sponsor: University Hospital, Geneva
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Surgery: Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=138, Recruiting, Sponsor: University Hospital, Geneva
- |||| Enrollment open, Trial initiation date, Trial primary completion date: Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients (clinicaltrials.gov) - Sep 28, 2014
P1/2, N=300, Recruiting, Sponsor: Jewish General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Nov 2013 --> Sep 2014 | Trial primary completion date: Dec 2014 --> Jun 2016
- || Trial primary completion date: Shared Decision Making in Graves Disease - Graves Disease (GD) Choice (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=147, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting | Initiation date: Nov 2013 --> Sep 2014 | Trial primary completion date: Dec 2014 --> Jun 2016 Trial primary completion date: Jul 2014 --> Dec 2014
- Trial completion, FDG PET: Accuracy of FDG-PET Scanning to Diagnose Malignant Thyroid Nodules (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=84, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Jul 2014 --> Dec 2014 Active, not recruiting --> Completed
- Trial primary completion date: Thyroid Disease Serum Repository (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=1000, Recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- New P2/3 trial: Low Level Laser Therapy for Autoimmune Thyroiditis (clinicaltrials.gov) - Sep 15, 2014
P2/3, N=43, Recruiting, Sponsor: University of Sao Paulo General Hospital
- prednisone / Generic mfg.
Trial primary completion date: Short-term Prednisone to Treat STA Study(SPTSS) (clinicaltrials.gov) - Sep 9, 2014
P4, N=40, Recruiting, Sponsor: Xinqiao Hospital of Chongqing
Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Jun 2014 --> Dec 2014
- | Trial completion, Metastases: Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Sep 6, 2014
P1, N=14, Completed, Sponsor: Michael Morse, MD
Trial primary completion date: Jun 2014 --> Dec 2014 No longer recruiting --> Completed
- Trial primary completion date, Metastases: A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin (clinicaltrials.gov) - Sep 5, 2014
P2, N=25, Recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Trial primary completion date: Sep 2014 --> Dec 2018
- Trial primary completion date: Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities (clinicaltrials.gov) - Sep 5, 2014
P2, N=99999999, Recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Sep 2014 --> Dec 2018 Trial primary completion date: Dec 2099 --> Jan 2099
- Trial primary completion date: Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=500, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Trial primary completion date: Dec 2099 --> Jan 2099 Trial primary completion date: Apr 2013 --> Apr 2015
- Trial completion: IIFHT: Interrelations Between FT3, FT4 and Pituitary TSH (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=1912, Completed, Sponsor: Klinikum L
Trial primary completion date: Apr 2013 --> Apr 2015 Recruiting --> Completed
- decitabine / Generic mfg.
Trial completion, Enrollment change, Metastases: Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 (clinicaltrials.gov) - Sep 4, 2014
P2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 12
- Trial primary completion date, HEOR: Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyro (clinicaltrials.gov) - Aug 29, 2014
P3, N=200, Recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Active, not recruiting --> Completed | N=40 --> 12 Trial primary completion date: Dec 2013 --> Nov 2014
- Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial primary completion date, IO biomarker: Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer (clinicaltrials.gov) - Aug 27, 2014
P2, N=25, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Nov 2014 Trial primary completion date: Sep 2014 --> Aug 2016
- ||| Trial completion, Trial primary completion date: A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=120, Completed, Sponsor: Medical University of South Carolina
Trial primary completion date: Sep 2014 --> Aug 2016 Enrolling by invitation --> Completed | Trial primary completion date: May 2015 --> Jul 2014
- Trial primary completion date: Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=60, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Enrolling by invitation --> Completed | Trial primary completion date: May 2015 --> Jul 2014 Trial primary completion date: Jun 2014 --> Jun 2015
- | carbimazole / Generic mfg., propylthiouracil / Generic mfg.
Enrollment closed, Trial primary completion date: Antithyroid Drug Treatment of Thyrotoxicosis in Young People (clinicaltrials.gov) - Aug 15, 2014
P3, N=160, Active, not recruiting, Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Trial primary completion date: Jun 2014 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2019 --> Dec 2014
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Epigenetic controller, Metastases: Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer (clinicaltrials.gov) - Aug 11, 2014
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2019 --> Dec 2014 N=25 --> 19
- Biomarker: Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: National Taiwan University Hospital
- lenvatinib / Generic mfg.
Clinical: An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=0, Available, Sponsor: Eisai Inc.
- thrombospondin-1 mimetic (ABT-510) / AbbVie
Trial completion, Metastases: Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Aug 5, 2014
P1/2, N=6, Completed, Sponsor: M.D. Anderson Cancer Center
N=25 --> 19 Active, not recruiting --> Completed
- Clinical: Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=40, Enrolling by invitation, Sponsor: University of Chicago
- Trial primary completion date: Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=90, Recruiting, Sponsor: Yonsei University
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2015
- Trial completion: Iodine Supplementation in Obesity (clinicaltrials.gov) - Jul 30, 2014
P=N/A, N=162, Completed, Sponsor: Swiss Federal Institute of Technology
Trial primary completion date: Mar 2014 --> Mar 2015 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Heterogeneity: TSH Receptor Antibody Heterogeneity in Children and Adolescents With Graves' Disease (clinicaltrials.gov) - Jul 27, 2014
P1, N=19, Completed, Sponsor: Children's Hospital Boston
Active, not recruiting --> Completed Recruiting --> Completed | N=100 --> 19
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: Tocilizumab Treatment in Graves (clinicaltrials.gov) - Jul 23, 2014
P3, N=32, Recruiting, Sponsor: Hospital Clinico Universitario de Santiago
Recruiting --> Completed | N=100 --> 19 Trial primary completion date: Dec 2013 --> Jun 2015
- Clinical: MyEndo-Thyroid: Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=2500, Not yet recruiting, Sponsor: International Islamic University Malaysia
- thyroxine / Generic mfg.
New P4 trial: Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism (clinicaltrials.gov) - Jul 12, 2014
P4, N=10, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- Trial completion: Thyroid and Fat Tissue Metabolism (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=41, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Dec 2013 --> Jun 2015 Recruiting --> Completed
- Trial termination: Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Jul 2, 2014
P1, N=35, Terminated, Sponsor: Yale University
Recruiting --> Completed Active, not recruiting --> Terminated
- | Trial completion: A Study of T3 Therapy in Patients With Hypothyroidism (clinicaltrials.gov) - Jul 2, 2014
P2, N=18, Completed, Sponsor: Ipe, LLC
Active, not recruiting --> Terminated Recruiting --> Completed
- Trial primary completion date: Investigating the Role of EN in NTIS Among Fistula Patients (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=40, Completed, Sponsor: Jinling Hospital, China
Recruiting --> Completed Trial primary completion date: Jan 2014 --> Apr 2014
- bortezomib / Generic mfg.
Enrollment change, Metastases: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Jun 27, 2014
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2014 --> Apr 2014 N=45 --> 24
- bortezomib / Generic mfg.
Trial completion, Enrollment change, Metastases: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy (clinicaltrials.gov) - Jun 27, 2014
P2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
N=45 --> 24 Active, not recruiting --> Completed | N=45 --> 24